MEGGLE returns to PBP World Meeting with mini tablet details

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) is returning as an exhibitor to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP 2018) in Granada, Spain.

MEGGLE has attended every PBP World Meeting since the biennial event was first staged in 1996.

The MEGGLE stand at Booth 17 at Granada’s PECG congress center will present highlights from the company’s huge range of lactose-based ingredients and excipients.

Mini-tablets poster

MEGGLE will also present a poster entitled: Development of Mini-tablets Containing 10 % Vitamin B2 and C: Characterization and Tableting Performance.

The mini tablets were developed in co-operation with Italian-based IMA Active S.p.A, whose scientists Anastasiya Zakhvatayeva, Federica Giatti and Caterina Funaro joined MEGGLE’s Vera Fichtner and Franz Karl Penz, Head of Application Technology, in authoring the paper on the new formulation.

Growing use

The use of mini-tablets continues to grow as an accepted option for small volume, high-value products, especially for specific patient populations. Single or multi-unit mini-tablet applications have the advantages of allowing fixed combinations and dose titrations.

“Furthermore, the typical diameter below three millimeters offers a superior approach for special populations like pediatric and geriatric patients or patients suffering from dysphagia.

The joint IMA/MEGGLE study aimed to demonstrate experimental design, equipment feasibility, lactose-based material performance, and critical material attributes within a typical mini-tablet manufacturing operation using an 8-station Prexima® 80 rotary press. Example formulations selected two different APIs and three functional excipients, Combi-Lac®, RetaLac® and spray-dried lactose, FlowLac® 100, to investigate compaction and release performances, as well as the impact of particle size.

Satisfactory performance

The poster shows how all materials showed performance within expected ranges when compactibility, tablet mass uniformity, and Vitamin B2 API release were investigated. Amongst other material specific properties, blend flowability was confirmed to be critical for tablet weight uniformity. Indirect correlation to API particle size was demonstrated for the investigated Vitamin B2 and C systems. Retesting mini-tablets after one month at 25 °C, and 60% RH showed no significant changes in tablet diameter or thickness. Breaking force variations were slightly larger.

Results clearly demonstrated equipment feasibility and material performance.

“We are looking forward to returning to the World Meeting to present this poster, as well as the opportunity to present our product portfolio, meet existing and potential customers and explore latest industry trends” Dr. Penz concluded.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About PBP 2018

The Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP) World Meeting has become a well-established pharma industry event, attracting scientists from all over the world. The event is biennial, with previous meetings held in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, and Glasgow (2016).

The 11th World Meeting, PBP 2018, is a four-day event opening March 19 at the Palacio de Exposiciones y Congressos (PECG) in Granada, Spain.

The event is expected to attract more than 1,300 delegates with close to 1,000 abstracts posted.

The conference and the accompanying ResearchPharm® exhibition provide a cross-disciplinary platform for pharmaceutical scientists working in all fields of drug product development in industry, academia and regulation.

PBP 2016 will have parallel sessions on industry-related topics presented by distinguished invited speakers along with two further parallel tracks for oral presentations by young or established scientists on Pharmaceutics, Biopharmaceutics and Pharma Technology.

More information at: http://www.worldmeeting.org/home.